Companies: 10,795·Total market cap: $144.5T
Prime Medicine, Inc.

Prime Medicine, Inc.

PRMENASDAQHealthcare● Active
$2.99
$-0.07(-2.29%)
Market Cap$540046176
P/E Ratio
52W High$6.94
52W Low$1.305
Overview

Prime Medicine, Inc. (PRME) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

prme · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 9 Wall Street analysts in the past 3 months

SellBuy

Buy

9 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
4
Sell
0
Strong Sell
0
Total: 9 · Buy rate: 55.6%

12-Month Price Target

High

$23.00

Consensus

$17.25

+476.0% upside

Low

$12.00

Median: $17 · Last Close: $3.00

The Prime Medicine, Inc. (PRME) analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month PRME price target is $17.25, representing +476.0% upside from the current price of $3.00.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $17 (476.0%)

Consensus Target

$17.25

476.0% upside

High Target

$23

667.9%

Low Target

$12

300.7%

Current Price

$3.00

as of today

Based on analyst price targets, the PRME stock price prediction for the next 12 months ranges from $12 to $23. The consensus PRME price forecast of $17.25 implies 476.0% upside from the current price of $3.00.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$3.031.14%

1-day model range: $2.99–$3.07. Peak: $3.07 (+1.14%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$2-50.0%
2028$1-63.8%
2029$1-69.2%
2030$1-71.8%
2031-73.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)54.3Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PRME · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$3.18SELL
MA 10$3.25SELL
MA 20$3.13SELL
MA 50$3.38SELL
MA 100$3.60SELL
MA 200$3.97SELL
Current $PRME · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$3.15SELL
EMA 10$3.18SELL
EMA 20$3.21SELL
EMA 50$3.36SELL
EMA 100$3.53SELL
EMA 200$3.64SELL
Current $PRME · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Citigroup2025-11-11
Maintains
NeutralNeutral
Chardan Capital2025-11-10
Maintains
BuyBuy
Citigroup2025-08-12
Maintains
NeutralNeutral
Chardan Capital2025-08-08
Maintains
BuyBuy
Citigroup2025-05-27
Downgrade ↓
BuyNeutral
JP Morgan2025-05-20
Downgrade ↓
OverweightNeutral
JMP Securities2025-05-20
Maintains
Market OutperformMarket Outperform
HC Wainwright & Co.2025-05-20
Downgrade ↓
BuyNeutral
Chardan Capital2025-05-19
Maintains
BuyBuy
Chardan Capital2025-03-20
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Prime Medicine, Inc. (PRME) stock. Of the recent 25 rating actions, 1 were upgrades and 3 were downgrades. 9 analysts currently cover PRME.

Analyst Recommendation Trends

Buy ratings11
Hold ratings01↑ +1
Sell ratings00

PRME analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$13M

↓ 58.7% YoY

Revenue Next Year

$23M

↑ 74.1% YoY

EPS This Year

$-1.00

EPS Next Year

$-0.91

↓ 8.9% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRME EPS of $-1.00 for the current fiscal year, based on estimates from 9 analysts. The PRME revenue forecast is $13M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PRME stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRME price target is $17.25 (+476.0% upside), with an analyst consensus of Buy.

The PRME short-term stock prediction for tomorrow is $3.03 (+1.14%). The PRME stock price prediction for 2027 estimates an average of $2. The PRME stock prediction for 2030 projects a range of $1–$1.

Prime Medicine, Inc. trades on NASDAQ under the ticker PRME. The PRME stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PRME forecast · 8 questions

According to 9 Wall Street analysts, the average 12-month PRME price target is $17.25, with a high forecast of $23.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +476.0% potential upside from the current price of $3.00.

PRME price targetWhat is PRME price targetPRME analyst price targetPRME 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.